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Antimicrobial resistance is considered to be one of the greatest challenges of medicine
and our civilization. Lack of progress in developing new anti-bacterial agents has
greatly revived interest in using phage therapy to combat antibiotic-resistant infections.
Although a number of clinical trials are underway and more are planned, the realistic
perspective of registration of phage preparations and their entering the health market
and significantly contributing to the current antimicrobial crisis is rather remote.
Therefore, in addition to planning further clinical trials, our present approach of phage
treatment carried out as experimental therapy (compassionate use) should be expanded
to address the growing and urgent needs of increasing cohorts of patients for whom no
alternative treatment is currently available. During the past 11 years of our phage therapy
center’s operation, we have obtained relevant clinical and laboratory data which not only
confirm the safety of the therapy but also provide important information shedding more
light on many aspects of the therapy, contributing to its optimization and allowing for
construction of the most appropriate clinical trials. New data on phage biology and
interactions with the immune system suggest that in the future phage therapy may
evolve from dealing with complications to targeting diseases. However, further studies
are necessary to confirm this promising trend.
Keywords: bacteriophage, phage therapy, antibiotic resistance, anti-phage antibodies, inflammation, reactive
oxygen species, compassionate use
IS IT ETHICAL TO CONTINUE NOT PURSUING PHAGE
THERAPY? (Henein, 2013)
On May 19, 2016 a review on antimicrobial resistance (AMR) commissioned by the UK Prime
Minister was published. AMR – considered to be a challenge to health and our entire civilization –
compared to terrorism and global warming – costs some 700,000 deaths annually and, if not
controlled, would lead to 10 million deaths by 2050, exceeding the toll of cancer. To prevent
medicine being cast back to the dark ages, the review suggests a number of actions promoting
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alternatives to drugs. Interestingly, phage therapy has been placed
at the top of a table presenting possible alternative products to
tackle infections (O’Neill, 2016).
Earlier this year another milestone document, also a review
delivered by 24 scientists from academia and industry and
commissioned by the Wellcome Trust, aimed at identifying the
prospective therapeutic replacements for antibiotics, considered
a number of key factors in this issue: (1) feasibility of informative
clinical trials, (2) magnitude of medical potential, (3) likelihood
and consequences of resistance, (4) level of current research
activity, (5) likely time to registration, and (6) activities enabling
validation and progression. Again, among the top ten approaches
which the group considered merited attention, phage therapy
was included, with earliest anticipated registration as of 2022
(Czaplewski et al., 2016).
The recent discovery of a plasmid-borne colistin resistance
gene heralds the emergence of truly pan-drug resistant bacteria
(McGann et al., 2016) and suggests that the competition between
the prospect of a pre-antibiotic era and registration of phages as
available medicinal products may be won by bacteria, with all
the dramatic consequences for our civilization emphasized by the
report mentioned above. This strongly suggests that our model of
phage therapy applied as experimental treatment should continue
to be implemented by other medical centers, in line with the
recent suggestions. As Gill and Young have pointed out: “. . .we
can see no compelling reason why phage therapy cannot be
made more widely available on compassionate use (CU) grounds
to patients aﬄicted with serious bacterial infections which are
refractory to standard treatments. A Hirszfeld Institute model
for such treatment could be implemented. As in Poland, the
availability of such a treatment would not only save lives but allow
for the collection of clinical data under well-documented clinical
conditions within the USA” (Gill and Young, 2011). In a more
recent article in Science, the authors recommend that: “major
hospitals should establish validated phage collections for CU
applications, where, in many instances, the bacterial pathogen
has been identified and could be tested for sensitivity to a library
of phages” (Young and Gill, 2015). This assumption was also
fully supported by other authors, who have emphasized that
introducing phage therapy into Western clinical practice in a
collaborative, CU fashion would not require further deviation
from the current standard of care (Kutter et al., 2015). What
is more, our approach does not constitute market placement
and practically places production of phage preparations for
our patients use outside of the scope of European Medicinal
Product Directive 2001/83/EC which has recently been fully
confirmed by legal analysis reported by Verbeken et al. (2014,
2016). “The debate is no longer about the pros and cons of
phage therapy, but rather about how we can move forward for
patients to benefit from this therapy. We are proposing to set up
dedicated public structures, National Reference Centers (NRC)
for bacteriophage therapy. These NRC will pilot these treatments
and put in place production of hospital-based bacteriophage
solutions, and application protocols that will ensure adequate
product quality, patient safety and monitoring of treatment
efficacy” (Debarbieux et al., 2016). We could not agree more,
as we have done so when our phage therapy center was
established in 2005, and have been continuing our activities
that have made it possible to gain invaluable experience derived
from patient care and careful monitoring clinical, laboratory
and immunological indices (Górski et al., 2012; Mie˛dzybrodzki
et al., 2012). The establishment of our center and earlier
activities of our Institute were facilitated by a 100 years
rich experience of former Soviet Union Countries (especially
Georgia and Russian Federation) covered by in-depth excellent
reviews (Chanishvili et al., 2009; Kutateladze and Adamia, 2010;
Chanishvili, 2016).
CLINICAL TRIALS VS. OBSERVATIONAL
STUDIES AND EXPERIMENTAL
THERAPY: THEIR ROLE IN FURTHER
ADVANCEMENT OF PHAGE THERAPY
One should also be aware that – in addition to randomized
clinical trials (RCT) – observational studies are an important
category of study designs, considered to be the next best
investigational method which may even yield comparable results
(Benson and Hartz, 2000; Concato et al., 2000). One should
cite here FDA Commissioner who has pointed out: “Although
randomized trials perform an essential role in the development of
therapies, we should not neglect the crucial and complementary
role that can be played by high-quality observational studies. . .
However, truly effective use of this volume of observational
data will require considerable methodological development,
including whether an observational study can provide sufficient
evidence to render a randomized trial unnecessary” (Califf
and Ostroff, 2015). In this context it is noteworthy that the
use of unapproved drugs outside of formal clinical trials in
patients posing difficult clinical dilemmas has been accepted
in a variety of countries including the US, Canada, Australia,
many European countries such as the UK, Germany, Austria,
Switzerland, France, Italy, as well as Japan and China. Such
treatment is most often called CU or expanded access (EA),
and its basic rules vary by country, most often encompassing
chronic, seriously debilitating or life-threatening disease, lack of
effective approved drugs for use in a given patient, approval by
an ethics committee, and informed consent. CU may involve the
use of a therapeutic product at any stage of its development,
including preclinical and early phases of clinical trials (Bedell,
2010; Whitfield et al., 2010; Walker et al., 2014). Thus, CU of
phage preparations may be considered an alternative to phage
therapy performed using preparations that would have been
formally approved following successful completion of clinical
trials.
Recently, a number of review articles covering various issues
related to phage therapy (including completed and ongoing
clinical trials, and regulatory and ethical issues at national,
EMA and FDA levels) have been published; therefore those
aspects will not be addressed here. Suffice it to say that
the first randomized double blind, placebo-controlled phase
I/II clinical trial on patients with otitis externa reported
symptom amelioration and a decrease of mean Pseudomonas
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aeruginosa titers in those patients associated with significant
phage replication in vivo (a 200-fold titer increase), as well
as a lack of adverse effects. However, a recently completed
phase II trial in children with acute Escherichia coli diarrhea
did not show superiority over the current standard of care.
The causes of this clinical trial’s failure are obscure at the
moment; increased levels of Streptococcus in those children raise
fundamental questions on the causative agent(s); in addition,
the relatively short duration of phage administration (4 days)
might also have contributed to the unsatisfactory results (Sarker
and Brussow, 2016). In 2017 the current Phagoburn clinical
trial evaluating phage therapy in the treatment of burn wounds
infected with E. coli and P. aeruginosa should be completed,
while Technophage has received FDA clearance to begin a
trial of a phage cocktail for the treatment of infected chronic
ulcers occurring in diabetic foot infections. New data on the
efficacy of phage therapy are therefore on the horizon; however,
new clinical trials addressing important clinical dilemmas (e.g.,
urinary tract infections) are urgently needed (Chan et al.,
2013; Ly-Chatain, 2014; Letkiewicz, 2015; Pirnay et al., 2015;
Vandenheuvel et al., 2015; Young and Gill, 2015; Chanishvili,
2016; Debarbieux et al., 2016; Expert round table on acceptance
and re-implementation of bacteriophage therapy, 2016; Verbeken
et al., 2016).
Our phage therapy unit has been accepting patients since
2005, so during the past 11 years, we have gained rich practical
experience resulting from direct patient care and monitoring
their clinical, laboratory and immunological parameters. Those
observations were summarized in our report published 4 years
ago (Mie˛dzybrodzki et al., 2012). In the subsequent years, we have
analyzed the data derived from more than additional 150 patients,
which essentially confirmed our earlier report, both with regard
to the therapy efficacy (good results achieved in approximately
40% of cases). Most importantly, we have re-confirmed the safety
of the therapy and indicated a minimal number of cases in which
it should have been discontinued due to side effects. The fact that
immunocompetence in patients with depressed immunity has
been evaluated as antibody responses to phage administered by
the intravenous (iv) route as well as historical data indicating that
patients were treated using that mode of phage administration
with outstanding efficacy and safety support our data and suggest
that iv phage therapy using purified preparations should be
seriously considered (Chanishvili, 2016; Speck and Smithyman,
2016).
Although current protocols of phage therapy carried out at
our institute have not supplied formal proof of phage therapy
efficacy – according to the requirements of evidence-based
medicine – they nevertheless provided valuable clinical and
laboratory data suggesting the optimal pathways for clinical
trials as well as novel and interesting data on phage interactions
with the immune system. For example, already 10 years
ago, we described successful eradication of MRSA intestinal
carrier status with subsequent eradication of genitourinary
tract infection with the same pathogen (Leszczyn´ski et al.,
2006); this was later confirmed by good results of urinary
tract infections using oral administration of bacteriophage
preparations (Mie˛dzybrodzki et al., 2012). Recently, Galtier et al.
(2016) from the Pasteur Institute using a mouse model and
oral phage administration showed 1000-fold titer reduction
of uropathogenic E. coli. As pointed out (Brussow, 2016),
this could lead to successful application of phage against
intestinal and by extension urinary pathogens. Our data strongly
suggest that at least some forms of urinary tract infections
can be treated with oral phage preparations targeting causative
pathogens.
Studies in vitro and in experimental animals suggest that
the use of phage cocktails may be superior to monotherapy
with a single phage targeting a given pathogen because of
a generally wider target range. In addition, the likelihood of
the development of phage resistance in bacteria is much less
likely using cocktails than single phages (Chan et al., 2013;
Vandenheuvel et al., 2015). However, some of our therapeutic
phages are sufficiently polyvalent as to cover more than 60%
of target strains. Moreover, as emphasized earlier, we have
achieved an approximately 40% rate of good results including
approximately 20% eradication rate using phage monotherapy
although the phage resistance phenomenon was occurring in the
course of treatment (Mie˛dzybrodzki et al., 2012). Furthermore,
our preliminary observations do not suggest clear clinical
superiority of cocktails vs. monovalent phage preparations This
finding is in agreement with the data of Brown et al. (2016)
who showed that the use of a phage cocktail was not superior
to using a single phage. Of note, high antiphage activity of sera
was observed in 43% of patients treated locally with cocktails,
in contrast to only 17% of patients on phage monotherapy,
which suggests that antibody responses to phage therapy may
vary depending on whether patients receive monotherapy or a
cocktail of phages. In fact, phages may induce different levels of
immunization, and antibody responses to some phages contained
in cocktails may be exceptionally high; this suggests that such
phages present in cocktails may induce adjuvant-like effects
(Łusiak-Szelachowska et al., 2016). One should also keep in mind
that the registration of a multicomponent phage cocktail should
be considerably more complex than a monovalent preparation, as
experienced by Pherecydes which was requested to demonstrate
stability of all components of their elaborate cocktail (Servick,
2016).
As pointed out, our experience suggests that despite
bacteriophage-resistant strain proliferation, phage therapy may
be successful, which may depend on virulence reduction in
such bacterial strains (lower growth rate, underexpression of
virulence genes, loss of pathogen’s ability to attach to human cells,
markedly reduced lifespan (Leon and Bastias, 2015). Without
the pressure of phages, resistant strains may revert to the
parental phenotype or may be displaced by non-resistant virulent
strains which may explain why prolonged phage therapy may
be sometimes more efficacious than a shorter protocol. Our
clinical data are confirmed by others (Capparelli et al., 2010)
who demonstrated in mice that phage-resistant bacteria may not
only be avirulent, but are also rapidly cleared by the immune
system and, importantly, induce a balanced anti-inflammatory
response (repression of transcription of the TNF-α and IFN-γ
genes and induction of expression of the IL-4 and IL-6 genes).
What is more, acquired phage resistance may be associated with
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greater sensitivity to antibiotics. Those important data strongly
suggest that – from the clinical point of view – the development
of phage resistance by relevant pathogens should not always
be considered as an undesired phenomenon, as it may cause
offending bacteria to become increasingly antibiotic-sensitive
and allow for renewed use of historically effective antibiotics
that have been rendered useless by the evolution of antibiotic
resistance. This approach has the potential to extend the effective
lifetime of antibiotics in our drug arsenal and broaden the
spectrum of those drugs, greatly reducing the burden on drugs
of the last resort, preserving them for future use (Chan et al.,
2013). The issue of combined use of phages and antibiotics is
of evident clinical significance. Some experimental data in vitro
and in experimental animals may suggest that such treatment
could be superior to phages or antibiotics alone; this problem
has recently been discussed in some detail (Torres-Barcelo and
Hochberg, 2016) and therefore will not be elaborated here.
Also, one can find some data in patients suggesting higher
efficacy of such combined therapy (Kutateladze and Adamia,
2010; Chanishvili, 2016). Most proponents of this treatment
highlight its potential. However, as rightly pointed out (Torres-
Barcelo and Hochberg, 2016), there are also potential drawbacks
of phage-antibiotic combinations such as the development of
double-resistant variants, similar to the effects of antibiotic
cocktails, which could have catastrophic consequences not only
for patients thus treated but for further prospects of successful
combat of AMR. Our policy has been to add antibiotics to phage
treatment solely in polyinfections in which no phage was available
to match an additional pathogen. Evidently, planned clinical
trials involving phage therapy should also include combination
treatment with antibiotics to provide more reliable data on this
important clinical dilemma.
ANTI-INFLAMMATORY EFFECTS OF
PHAGES
One of the most promising aspects of phage therapy is
its remarkable anti-inflammatory action. We have noted a
significant decrease in mean C reactive protein (CRP) values
and leukocyte counts, with a similar tendency of erythrocyte
sedimentation rate (Mie˛dzybrodzki et al., 2009). In some
patients the reaction of CRP was dramatic and decreased
from 50 to 5 mg/l within 2–3 weeks of the treatment even
though complete eradication of infection was not achieved.
This suggests that phage can exert its anti-inflammatory action
by at least two mechanisms: one dependent on its well-
known anti-bacterial action, and another which acts directly on
phenomena responsible for the development of inflammatory
processes. In fact, we have demonstrated that phage can
diminish cellular infiltration of allogeneic skin transplants
in mice and activation of the nuclear transcription factor
NF-kappa B (which leads to expression of proinflammatory
cytokines, chemokines, and adhesion molecules (Górski et al.,
2006a). A short tail fiber protein, tail adhesion gp12, mediates
adsorption of T4 phage to E. coli, binding LPS. Recently,
our group demonstrated that recombinant gp12 counteracts
proinflammatory effects of LPS in vivo, causing the reduction
of serum IL-1 and IL-6 levels as well as a decrease of
inflammatory infiltration in spleen and liver (Miernikiewicz
et al., 2016). What is more, we have observed that phages
and their surface proteins do not stimulate inflammatory
mediator and reactive oxygen species (ROS) production when
administered to mice (Miernikiewicz et al., 2013). This confirms
and extends our earlier reports indicating that T4 phage
lysates and its purified preparations induce only minimal
levels of respiratory burst in whole blood monocytes and
neutrophils while staphylococcal phage preparations do not
stimulate the production of ROS at all (Borysowski et al.,
2010). Furthermore, phages diminish ROS production induced
by bacteria and endotoxin (Mie˛dzybrodzki et al., 2008), which
highlights their potential in the treatment of sepsis (Weber-
Da˛browska et al., 2003). As shown by our group, phages
do not induce granulocyte degranulation (Borysowski et al.,
submitted for publication), their administration to patients is
not associated with leukocytosis (conversely, as stated earlier,
they may reduce the number of circulating leukocytes in
patients with bacterial infection; it is also noteworthy that
phage therapy does not cause eosinophilia) (Mie˛dzybrodzki
et al., 2012). In conclusion, our studies performed in vitro as
well as in vivo in experimental animals and patients strongly
suggest that phages may exert anti-inflammatory effects that
can be useful clinically. The success of phage therapy depends
on the ability of phages to migrate to infected tissues and
achieve concentrations necessary to eradicate infection and
exert anti-inflammatory action. In this regard, we proposed
to engineer phages armed with tissue-specific peptides – this
methodology, not necessarily involving genetic manipulations,
may significantly enhance the effectiveness of phage therapy
(Górski et al., 2015).
PHAGES AND THE IMMUNE SYSTEM
Górski and Weber-Da˛browska (2005) proposed that phages may
mediate immunomodulatory, probiotic-like functions and this
phenomenon could be relevant in regulating local immunity
in the intestinal tract where phages are an abundant part of
the microbiome. What is more, phage translocation from the
intestines might contribute to phages mediating such probiotic-
like functions also in other parts of the body (Górski et al.,
2006b). As the evidence on phage engagement in regulating
immunity is accumulating, those data add credence to our
hypothesis. In fact, our comprehensive review addressing the
issue of phage interactions with the immune system and their
possible practical implications, especially in relation to the
therapy, highlights the potential role of phages as clinically
useful immunomodulators. Our data indicate that about half
the patients prior to phage therapy are immunodeficient;
although the therapy may cause some fluctuations of immune
parameters, its beneficial effects are not correlated with upgraded
immunity (except for an increase of phagocytosis noted in some
patients which also appears to have some positive prognostic
value). Therefore, the therapeutic effects of phage therapy are
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associated with its anti-bacterial and anti-inflammatory action
rather than resulting from correction of depressed immunity,
so the potential vaccine-like effect of phages is not responsible
for their curative activity (Górski et al., 2012). Our data
on monitoring phagocytosis by neutrophils and monocytes
of patients on phage therapy suggest that the therapy may
instead correct existing deficiencies in phagocyte functions
(see above). In fact, we have shown that phages – both
in vitro and in vivo – do not adversely affect the ability of
phagocytes to kill bacteria – both standard strains as well
as specific pathogens isolated from patients (Jon´czyk-Matysiak
et al., 2015). Also, phages do not impair migratory activity of
human phagocytes in vitro (Kurze˛pa, 2011), whereas they may
markedly diminish tissue infiltration with those cells at the
foci of inflammation (Górski et al., 2006a; Miernikiewicz et al.,
2016).
An important clinical dilemma is whether phage therapy may
be safe and efficient in immunosuppressed host (Borysowski
and Górski, 2008). Our data obtained in patients with
antibiotic-resistant infections who frequently have associated
immunodeficiency confirm the value of the therapy in this
syndrome. Also, phages have been successfully applied in
cancer patients and renal allograft recipients (Borysowski and
Górski, 2008). Those clinical observations were also confirmed
experimentally by our group (Zimecki et al., 2010), who described
the protective effects of phage therapy in immunodeficient mice
subjected to myeloablative and immunosuppressive conditioning
followed by bone marrow transplant and infected by sublethal
and lethal dose of Staphylococcus aureus. Of note, we have shown
that phage preparations do not enhance inflammatory processes
in experimentally induced autoimmune disease in mice and
may even have protective and therapeutic action (Mie˛dzybrodzki
et al., unpublished data). These findings may suggest that
phage therapy is also safe in patients with autoimmune
disorders. If confirmed, those data should be especially relevant
as such patients are especially prone to multidrug resistant
infections.
ANTIBODY RESPONSES TO PHAGE
THERAPY
Animal models allow for comprehensive studies of immune
responses to bacteriophages in vivo. Induction of specific
anti-phage antibodies has probably been the most extensively
studied in mice, resulting in a multi-faceted description
of this phenomenon. This comprises dose, schedule and
route of administration effects, with regard to primary
classes of immunoglobulins, and with reference to various
immunogenicity of particular structural elements of
bacteriophages.
A model bacteriophage T4 has been demonstrated to be
able to induce specific antibody both after phage injection into
peritoneum (Da˛browska et al., 2014) and in long-term per os
treatment (Majewska et al., 2015). In the experimental model
of per os treatment, efficient induction of specific antibody
production required long exposure of animals to the phage.
The authors observed a significant increase in serum IgG on
day 36. Once the IgG level reached a peak, it remained high
throughout the experiment, even after the phage was removed
from the diet. It did not, however, impact gastrointestinal
phage transit. Interestingly, no clear IgM peak preceded the
IgG boost, which is in contrast to immunization by parenteral
applications, where a significant increase of IgM has been
reported (Da˛browska et al., 2014; Hodyra-Stefaniak et al.,
2015).
A characteristic feature of oral administration is the
secretory IgA production in the gut. In fact, this can also
be observed as a result of bacteriophage administration per
os, but again its induction requires long and high dose
exposure to bacteriophage. An increase in secretory IgA
was reported on day 79 of the oral treatment with T4.
Importantly, the increase of phage-specific IgA in the gut
correlated with the lack of viable phage particles detected in
the feces. Thus, specific anti-phage IgA can be considered as
a factor limiting phage viability in the gut (Majewska et al.,
2015).
In order to draw a general conclusion about T4 phage
immunogenicity for the needs of therapeutic approaches, an
estimated adequate dose in humans was calculated: 2 × 1010
pfu per mouse corresponds to 7 × 1013 pfu per human patient
daily (using a simplification of volumes as proportional to weight
across species). The dosage used in therapeutic approaches in
humans is usually much lower: in the 20th century, tablet or
liquid formulations that were used in oral treatment of humans
contained 105 to 1011 pfu/dose (Sulakvelidze et al., 2001), while
daily therapeutic phage doses used in the Phage Therapy Unit of
the Institute of Immunology and Experimental Therapy (IIET)
in the years 2008–2010 ranged between 3 × 107 and 6 × 1010pfu
per patient (Mie˛dzybrodzki et al., 2012). Also in T4 phage safety
tests conducted by Bruttin and Brüssow (2005) the total amount
of phage preparations administered to human volunteers was
much lower and equaled 9 × 107 pfu; no specific antibodies
were detected following the safety tests. Taking into consideration
the unusually high dosage and the time of continuous treatment
that was necessary to elicit a humoral response (2 weeks in
the case of IgG and as long as 2 months in the case of IgA),
T4 phage immunogenicity in oral administration was defined
as weak.
Microbiological assessment of bacterial fecal flora during
the prolonged feeding of mice with T4 showed no substantial
differences between phage-treated and control mice. The
emergence of phage-resistant E. coli strains was observed in
phage-treated mice very late: on day 92 (Majewska et al.,
2015). This fact is important in the light of recent studies of
the human microbiome that have demonstrated links between
dysbiosis in the gut and numerous health problems, both
located within the gastrointestinal tract and in other parts of
the body (Kau et al., 2011). Animal studies suggests that the
impact of orally applied phage on gut natural microflora is
minimal.
Structural proteins of bacteriophages may differ in their
individual immunogenicity. Furthermore, the route of
administration may play a role in the resulting ability of
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the proteins to induce specific antibodies. T4 phage proteins
reported as highly immunogenic when applied intraperitoneally
were major capsid protein gp23 and highly antigenic outer
capsid protein gpHoc (Da˛browska et al., 2014). However,
oral administration of this phage resulted in immunization
mostly to gpHoc and gp12 (tail spike) (Majewska et al., 2015).
These data highlight the fact that route of administration
plays a role in determining the fate of phage particles in the
context of the specific humoral response. Gp12 is crucial in
the process of phage adsorption and infection of bacterial
host cells; therefore, the humoral response directed toward
this particular protein may impair antibacterial properties of
the phage and consequently impact the efficacy of phages as
therapeutic agents. Hence, further studies aiming to identify the
molecular basis for this response may, in the future, facilitate
the optimal choice and design of phage use in therapy. On the
other hand, a high-level humoral response may turn out to
be beneficial in some scenarios. T4 phage has been effectively
used as a phage display platform for foreign antigens, often
displayed as Hoc fusion proteins (Rao group: Jiang et al., 1997;
Sathaliyawala et al., 2006; Shivachandra et al., 2006, 2007).
In this case, the ability of Hoc protein to induce a high-level
humoral response may result in more efficient immunization
to the fusion protein, which is highly desirable in vaccine
development.
Since bacteriophages can be neutralized by specific antibodies
in vivo and in vitro, a few possible mechanisms of phage
inactivation have been considered. The most straightforward
one was direct interaction of antibodies with phage proteins
that are necessary for infection of bacterial cells; phage cannot
attack bacteria since these proteins have been occluded by
antibodies (Jerne and Avegno, 1956). However, anti-head
immunization has also been demonstrated to reduce phage
activity. In this case aggregation of phage particles as well as
the antibody-dependent complement pathway were proposed
as the mechanisms of phage inactivation (Da˛browska et al.,
2014).
Our recent papers have analyzed the practical issues of
neutralizing antibody responses to phages in their clinical context
based on the largest patient material ever available (Łusiak-
Szelachowska et al., 2014, 2016). As noted, several key factors
are responsible for those antibody responses: patients’ immune
status, route of phage administration, antigenicity of a given
phage, and monotherapy vs. phage cocktails. Furthermore, the
clinical significance of the production of anti-phage antibodies is
unclear at the moment, as we have not confirmed a correlation
between their appearance and therapy outcome. Conversely,
good clinical results may be achieved with concurrent high
serum neutralizing antibody levels against administered phage.
Interestingly, anti-staph phage that effectively controls S. aureus
growth and reduces bacterial viability both in vitro and in a
skin infection mouse model loses its killing effect when the
phage is cultured in the presence of human blood (Pincus
et al., 2015). It may well be that local antibody interactions
with phage at the foci of infection are more relevant for
therapy success than serum antibody levels, whose raised values
may – paradoxically – at least in some patients indicate a good
clinical outcome signaling the recovery of the immune system
and its more active participation in clearing infection. Our
data suggesting that recovery of phagocytosis may be a good
prognostic sign for therapy outcome provide food for thought for
such hypothesis.
FUTURE PROSPECTS OF PHAGE
THERAPY
It has been highlighted that phages – unlike classical antibiotics –
are biological entities of incredible diversity and adaptability
and many surprises may be in store (Young and Gill,
2015). The above mentioned data suggest that phages could
interfere with some viral and fungal infections which could
extend its potential therapeutic value beyond well-known
antibacterial action. One could list here our recent data
showing that T4 phage can inhibit infection of the target
cells by an adenovirus (Przybylski et al., 2015) as well as
the data from Stanford indicating that P. aeruginosa phage
inhibits Aspergillus (Penner et al., 2016), which suggest that
future applications of phage therapy may extend beyond its
well known antibacterial action. In recent years, we have
been facing unprecedented growth of interest in the human
microbiome which has emerged as an important factor in
human physiology and disease including obesity and diabetes,
cancer and susceptibility to its chemotherapy, cognition and
depression, etc. Therefore, manipulation of the microbiome
is currently believed to have great potential for efficient
therapy of disorders posing a challenge to medicine and
civilization (Blaser, 2014). Phage-mediated immunomodulation
of the enteric immune system and microbiome may be an
important key to the success of this strategy (Górski et al.,
2003, 2006b). One cannot thus exclude that the future phage
therapy may be focused on our microbiome. Today, we
can use phage therapy to combat urinary tract infections
secondary to kidney stones which treats complications rather
than a disease itself. Gut microbiota is unique in kidney
stone disease (Kelsey, 2016). One could therefore envisage
using phages to manipulate gut microbiome to treat and
prevent the development of renal stones not only their
complications. Moreover, phage ability to reduce the production
of ROS and inflammatory processes (e.g., tissue infiltration
by leukocytes) could be helpful to ameliorate the clinical
course of patients with disorders where those phenomena
are relevant (e.g., graft rejection, inflammatory bowel disease,
etc.).
While the Canadian doctor F. d’Herelle discovered phages,
another Canadian medical authority has emphasized: “The
good physician treats the disease, the great physician treats
the patient who has the disease” (Sir William Osler). A good
example of this philosophy is the recent data suggesting
that intensive glucose lowering protocols cause more harm
than benefit in patients with type 2 diabetes (The Action to
Control Cardiovascular Risk in Diabetes Study Group, 2008).
Patients with antibiotic-resistant infections have complex
clinical problems and frequently pose difficult clinical
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dilemmas, resistant infection being an important, but not the
sole component of their morbidity. The main purpose of a
physician should be to provide optimal therapy considering
all aspects of a patient’s disorder, that is to heal the patient,
not just eradicate infection (certainly not at any cost). Some
reviews on phage therapy appear to disregard this principle;
in this regard, one could cite an important recent opinion
of Nature Medicine: “researchers need to reach back to the
patients, but in a way that steers clear of giving medical
advice” (Knoepfler, 2016). Phage therapy has the potential to
go beyond from merely treating an infection in a patient
to treating its causes and prevent further complications, a
promise that requires further studies and confirmation. Tailoring
medical treatment to the individual characteristics, needs and
preferences of each patient fulfills the promise of a new era
of medical product development referred to as personalized
(precision) medicine (Food and Drug Administration, 2013).
Phage therapy constitutes an excellent example of this novel
trend.
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